Ajax Therapeutics

0 followers

Ajax is targeting hematologic malignancies with greater precision by applying state-of-the-art computational chemistry and structural biology throughout the drug discovery and development process to create best-in-class therapies for significant unmet medical needs.

Industries

Employees

1-10

Links


Org chart

Martin Vogelbaum
Interim CEO
Collapse
David Waller
Senior Vice President
David Steensma
Chief Medical Officer
Craig E. Masse
SVP, Discovery Research

Board & advisors

Eric S. Fischer
Scientific Advisor
Ramy Farid
Director
Ross Levine
Director